Acute Myeloid Leukemia Subtype-Specific Prognostic Value of NGS in…
Genetic testing now pinpoints which AML patients face dire versus favorable odds, enabling doctors to tailor intensity of treatment and post-MPN AML deserves separate prognostic consideration.
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
Dapagliflozin in acute myocardial infarction with type 2 diabetes
A diabetes medication dramatically cut heart failure events after heart attacks in diabetic patients, addressing a gap in evidence for this specific high-risk group.
Near-term implementable findingNewly diagnosed acute myeloid leukemia in Fit patients
New combination therapies and decision tools help doctors choose between gentler and intensive AML treatments based on individual patient genetics and disease features.
Near-term implementable findingEvidence from two large prospective cohorts
A new blood marker combining cholesterol and inflammation measures independently predicts heart disease and metabolic illness risk across diverse populations.
Standard additionOPTIM: a randomized phase II trial of nivolumab followed by…
Attempting dual immunotherapy after checkpoint failure worsened outcomes, redirecting research toward more effective salvage strategies for advanced throat cancer.